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Cancer represents a unique cell deregulation disease in
patients, therefore it has become clear in recent years that
successful treatment will depend on personalized cancer
therapy. The immune response against cancer is activated
when antigen presenting cells (APC) pick up tumor anti-
gens and present them to CD4 helper cells on MHC II
molecules and to cytotoxic T lymphocytes (CTL) on
MHC I molecules, respectively. Successful design of adop-
tive immunotherapies should thereby encompass three
types of immune cells: APC, CD4 helper lymphocytes and
CD8 CTL. We employed internal cell localization signals
(ILS) to target endogenous antigens to both MHC I and
MHC II molecules. We loaded dendritic cells (DC) with in
vitro transcribed (ivt) mRNA coding for 5 different
cancer-testis-antigens (CTAs) (GAGE-1, MAGE-A4,
NY-ESO-1, SSX4 and XAGE-1) fused to ILS signals.
These DCs which presented CTAs at high levels on MHC
I and II were used for in vitro priming of unseparated PBL
allowing activation and co-interactions of CD4 and CD8 T
cells with concordant selection for immunodominat CTA.
Expression of CD154 on CD4 T cells and CD137 on CD8
T cells were used for specific cell sorting, enabling isola-
tion of CD4 T cell clones specific for 4 of 5 antigens to be
obtained in one experiment. These clones used multiple
TCR for CTA recognition as well as different MHC II allo-
types for antigen presentation. Multiple CD8 T cell clones
recognizing 5 of 5 CTA were also isolated. These clones
used different TCRs and epitopes were presented by differ-
ent MHC I allotypes. Therefore, this methodology enabled
high throughput isolation of many different cancer specific
CD4 and CD8 T cells. T cell priming using CTA fused to
ILS signals was also assessed for priming efficiency in an
in vivo DC vaccination model. We used NOD/scid IL2Rg-
null (NSG) mice deficient for T-, B- and NK-cells to
engraft with human peripheral blood mononuclear cells.
Autologous DC were transfected with ivt-mRNA of
melan-A fused to ILS signals or with melan-A ivt-mRNA
without these signals. Upon second vaccination mice
reconstituted with human PBL, were sacrificed and speci-
fic cytokine secretion by human CD8 T cells was mea-
sured upon co-cultivation with melanoma cell lines.
Superior activation of melanoma specific CD8 T cells was
seen when DC with melan-A fused to ILS signals was used
for vaccination. Taken together, these data show that phy-
siological ILS signals could be used to enable efficient
priming of CD4 and CD8 T cells in vitro as well as in vivo.
The isolated TCR provide potential reagents for use in
adoptive transfer of genetically engineered T cells.
Furthermore, DC loaded with ILS-fused CTA could be
used as efficient DC vaccines for priming of both CD4 and
CD8 T cells in vivo.
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